Revolutionary. A game-changer. Spine-chilling. Those are some of the words experts used to describe fresh data for lenacapavir, a twice-yearly shot developed by Gilead Sciences for the prevention of HIV.
Their enthusiasm stems from a more succinct word: zero. That is the number of cases of HIV that developed in the women and adolescent girls who received the drug in a huge study conducted across dozens of sites in South Africa and Uganda.
Lenacapavir has the potential to at long last move the needle on the incidence of HIV. The virus caused about 1.3 million infections and 630,000 deaths in 2022.
This preventive drug, if given to enough at-risk women, could be the way to get close to eliminating pediatric HIV, an expert said.
Another talked about finally bending infection curves in young women and adolescent girls, who account for 77 percent of new infections among younger people in sub-Saharan Africa.
However, none of that would happen without the right pieces in place to get the drug to everyone who needs it as soon as it receives regulatory clearance. That is an all-hands-on-deck effort that should be underway now.
Lenacapavir’s advantage is its unique mechanism and monthslong activity. While other HIV antivirals target enzymes the virus needs to replicate, lenacapavir takes aim at the capsid, an eggplant-shaped shell made up of hundreds of proteins that carefully assemble to protect the virus’ genetic material.
It turns out disrupting that shell works beautifully as a prophylaxis: In the trial, there were no HIV infections in the more than 2,100 women who received the drug, compared with infection rates of 1.5 percent and 1.8 percent in women taking Truvada or Descovy, two types of daily pills to prevent HIV infection (also known as PrEP).
“I’ve been doing this for almost 40 years, I have never, ever seen a result like this before,” Centre for the AIDS Programme of Research in South Africa director and infectious disease epidemiologist Salim Abdool Karim said. “To see a 100 percent efficacious product? It just blew my mind.”
The center enrolled several hundred women for the study, although Abdool Karim was not directly involved.
A separate prevention study of lenacapavir in men who have sex with men and transgender people is underway, after which Gilead plans to ask for regulatory approval. (The drug is already on the market in the US and elsewhere as a treatment for HIV.)
However, the data in young women are already extraordinary. The existing options for PrEP — whether daily pills, the dapivirine vaginal ring, or ViiV Healthcare’s bimonthly shot cabotegravir — have not moved the needle much on rates of infection among young women.
“A daily intervention needs a daily decision: ‘I’m going to protect myself,’” said Linda-Gail Bekker, director of the Desmond Tutu HIV Centre at the University of Cape Town and an investigator in the trial.
A wildly effective, twice-annual shot could make a huge difference in bending infection curves, particularly among women and infants.
Yet this astounding success can only come to fruition if lenacapavir reaches the people who need it. That comes down to access and delivery: Lenacapavir needs to be made at a volume that it can be widely available, at a price that makes it widely accessible and distributed in a way that makes it easy and appealing for everyone to stick with.
The ball is in Gilead’s court on the issues of price and supply. Gilead is, so far, saying all the right things.
The same day it revealed the astonishing trial results, the biotech company announced a two-pronged approach to ensuring lenacapavir can be widely available in places being hit hardest by HIV. It is to form license agreements that allow generic firms to make and sell the drug in low-resource countries hard hit by the HIV epidemic, a strategy used successfully in the past.
Until that generic supply is up and running, the company says it would set aside supply for those regions. That has elicited cautious optimism.
However, Gilead would also need to commit to transparency at every step of the process.
While the company has made substantial efforts to ensure people in low and middle-income countries can access its HIV therapies, it also has been criticized for some of its tactics around the price and development of certain medicines.
Global health experts would like to better understand which countries would have access to low-cost generic versions of the drug, and be assured that the company would work to transfer not only patents, but also know-how to ensure a speedy increase in manufacturing.
That third piece of the equation, delivery, would require a huge effort by global health agencies and their partners to study the most effective way to get the treatment to at-risk groups — not just once, of course, but every six months during the years they might be vulnerable to infection.
The work these groups have already done to provide existing forms of PrEP provides a good foundation for distributing lenacapavir, Unitaid senior strategy lead Carmen Perez Casas said. Meanwhile, studies would need to be quickly designed and funded to understand the best way to ensure broad and consistent use of the biannual shot.
This new drug, while astounding, does not obviate the need to keep pushing for an effective HIV vaccine. Yes, the new drug would likely meaningfully reduce infections (which also reduces transmission), but a vaccine that ideally can be administered before puberty is the key to eradicating this deadly virus.
Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, healthcare and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News.
A gap appears to be emerging between Washington’s foreign policy elites and the broader American public on how the United States should respond to China’s rise. From my vantage working at a think tank in Washington, DC, and through regular travel around the United States, I increasingly experience two distinct discussions. This divergence — between America’s elite hawkishness and public caution — may become one of the least appreciated and most consequential external factors influencing Taiwan’s security environment in the years ahead. Within the American policy community, the dominant view of China has grown unmistakably tough. Many members of Congress, as
After declaring Iran’s military “gone,” US President Donald Trump appealed to the UK, France, Japan and South Korea — as well as China, Iran’s strategic partner — to send minesweepers and naval forces to reopen the Strait of Hormuz. When allies balked, the request turned into a warning: NATO would face “a very bad” future if it refused. The prevailing wisdom is that Trump faces a credibility problem: having spent years insulting allies, he finds they would not rally when he needs them. That is true, but superficial, as though a structural collapse could be caused by wounded feelings. Something
Former Taipei mayor and Taiwan People’s Party (TPP) founding chairman Ko Wen-je (柯文哲) was sentenced to 17 years in prison on Thursday, making headlines across major media. However, another case linked to the TPP — the indictment of Chinese immigrant Xu Chunying (徐春鶯) for alleged violations of the Anti-Infiltration Act (反滲透法) on Tuesday — has also stirred up heated discussions. Born in Shanghai, Xu became a resident of Taiwan through marriage in 1993. Currently the director of the Taiwan New Immigrant Development Association, she was elected to serve as legislator-at-large for the TPP in 2023, but was later charged with involvement
Out of 64 participating universities in this year’s Stars Program — through which schools directly recommend their top students to universities for admission — only 19 filled their admissions quotas. There were 922 vacancies, down more than 200 from last year; top universities had 37 unfilled places, 40 fewer than last year. The original purpose of the Stars Program was to expand admissions to a wider range of students. However, certain departments at elite universities that failed to meet their admissions quotas are not improving. Vacancies at top universities are linked to students’ program preferences on their applications, but inappropriate admission
RSS